Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)

Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)

There is an unmet need for predictive biomarkers in metastatic renal cell carcinoma (mRCC) therapy. The phase IV MARC-2 trial searched for predictive blood biomarkers in patients with predominant clear cell mRCC who benefit from second-line treatment with everolimus. In an exploratory approach, pote...

Full description

Bibliographic Details
Main Authors: Philip Zeuschner, Sebastian Hölters, Michael Stöckle, Barbara Seliger, Anja Mueller, Hagen S. Bachmann, Viktor Grünwald, Daniel C. Christoph, Arnulf Stenzl, Marc-Oliver Grimm, Fabian Brüning, Peter J. Goebell, Marinela Augustin, Frederik Roos, Johanna Harde, Iris Benz-Rüd, Michael Staehler, Kerstin Junker
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cancers
Subjects:
biomarker
everolimus
metastatic renal cell carcinoma
second-line
phase IV
Online Access:https://www.mdpi.com/2072-6694/13/11/2594

Internet

https://www.mdpi.com/2072-6694/13/11/2594

Similar Items